AVEO Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVEO Pharmaceuticals

AVEO 15.00

0.0%

Jan 19 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	5/2/2012 7:40:27 PM
	of 8

finance.yahoo.com Maybe not a big issue, but.....pounding the table…. Ficlatuzumab (AV-299), discovered by AVEO through its Human Response Platform™ (HRP), is a potent anti-HGF/c-MET antibody… Does not support SM+/c-Met low sub-group analysis and result (Encouraging Signals of Anti-tumor Activity in Distinct Subpopulations) from: ”AVEO Announces Preliminary Results of Exploratory Phase 2 Study Evaluating HGF Inhibitor in First-Line Patients with Advanced Lung Cancer” Not to mention that there is great result discrepancy for Iressa alone in SM+/c-Met low group. If they can put such a BS in PR, how can one trust them with TIVO-1?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next